A survey of 48 oncologists by Leerink found that the use of a poly ADP-ribose polymerase (PARP) inhibitor in second-line maintenance of ovarian cancer could increase from about 45 percent to about 55 percent during the next 12 months. The class' utility there may be starting to plateau, but clinicians polled liked the prospects of expanded use into the front-line maintenance setting, as well as PARP retreatment.